Topivert Pharma Ltd., of London, said it dosed the first patients in a phase I/IIa proof-of-concept study in the U.S. testing TOP1630 ophthalmic solution for the treatment of dry eye syndrome. The study is expected to report in the second half of this year. TOP1630 is a narrow spectrum kinase inhibitor, or NSKI, which has demonstrated efficacy in in vitro and in vivo inflammatory models.